SymBio Pharmaceuticals Limited (TYO:4582)
Japan · Delayed Price · Currency is JPY 92.00
-2.00 (-2.13%)
At close: Jan 21, 2026
SymBio Pharmaceuticals Company Description
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally.
It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; SyB L-1702, an RI administration under the TREAKISYM name; and C-1101, an antiviral drug BCV injectable and oral formulations against double-stranded DNA viruses.
The company was incorporated in 2005 and is based in Minato, Japan.
SymBio Pharmaceuticals Limited
| Country | Japan |
| Founded | 2005 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 108 |
| CEO | Fuminori Yoshida |
Contact Details
Address: Toranomon Towers Office Minato, 105-0001 Japan | |
| Phone | 81 3 5472 1125 |
| Website | symbiopharma.com |
Stock Details
| Ticker Symbol | 4582 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3383050006 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Fuminori Yoshida | Chief Executive Officer |
| Takeo Okuno | Chief Financial Officer |